• Pfizer reported new seven-year data from the Phase 3 CROWN trial at ASCO 2026, highlighting LORBRENA for untreated ALK-positive advanced non small cell lung cancer.
• The company also presented Phase 3 BREAKWATER results in metastatic colorectal cancer using a BRAFTOVI based combination.
• In metastatic prostate cancer, TALZENNA plus XTANDI showed a 52% reduction in the risk of progression or death versus standard care.

For investors tracking NYSE:PFE, these oncology updates arrive with the stock trading at $25.63. The share price is up 16.9% over the past year, although it is down 20.1% over three years and down 15.1% over five years. This mixed share price history may lead some investors to pay close attention to how late stage cancer data fits into Pfizer’s broader pipeline story.

These ASCO 2026 readouts span lung, colorectal and prostate cancers, three areas with significant treatment needs. As regulators, clinicians and payers review these findings, investors may watch for signals on how quickly these therapies could influence treatment decisions and Pfizer’s future oncology profile.

Stay updated on the most important news stories for Pfizer by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Pfizer.

For investors, these ASCO 2026 results and Pfizer’s recent alliances point to a clear focus on oncology where competitors like Merck, Bristol Myers Squibb and AstraZeneca are also active. The seven year CROWN data for LORBRENA in ALK positive lung cancer, the BREAKWATER colorectal data with BRAFTOVI combinations, and TALAPRO 3 results for TALZENNA plus XTANDI all sit in commercially established tumor types with defined biomarkers. That combination, plus the up to US$10.5b Innovent collaboration and the Sarah Cannon Research Institute tie up, gives Pfizer more shots on goal across both small molecules and complex biologics while trying to manage an earnings and patent reset.

How This Fits Into The Pfizer Narrative

• The strong late stage readouts in lung, colorectal and prostate cancer align with the narrative focus on oncology and rare disease assets as key drivers for future revenue and earnings.
• The heavy oncology spend, including the Innovent deal, could test assumptions in the narrative around margin expansion and debt management if development timelines or uptake are slower than expected.
• The breadth of early stage ADC and multi specific antibody programs from Innovent, plus new trial capacity from Sarah Cannon’s Accelero model, may not be fully reflected in existing community narratives that were written before these announcements.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Pfizer to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Analysts have flagged that earnings are forecast to decline over the next few years, so additional oncology spend from deals and trials could pressure near term profitability if product uptake is slower than hoped.
• ⚠️ Dividend and debt coverage are already highlighted as risks, so layering large milestone commitments and co development costs on top of this may raise questions about payout sustainability and balance sheet flexibility.
• 🎁 The new oncology data support the view that Pfizer is adding clinically meaningful therapies in cancer, which could help offset revenue pressure from patent expirations if these medicines reach broad use.
• 🎁 Simply Wall St’s assessment that Pfizer trades below its estimated fair value suggests investors are not fully pricing in potential contributions from LORBRENA, BRAFTOVI combinations, TALZENNA plus XTANDI and the expanded early stage pipeline.

What To Watch Going Forward

From here, watch how quickly Pfizer converts these data into regulatory submissions, new or expanded labels and real world adoption, especially versus rival oncology products from Merck, Bristol Myers Squibb and others. Progress on closing and implementing the Innovent partnership, plus any updates on how Sarah Cannon’s Accelero model is affecting enrollment times, will also matter for assessing R&D productivity. Finally, track how management talks about allocating cash between oncology deals, pipeline investment, debt reduction and dividends as more cancer results like CROWN, BREAKWATER and TALAPRO 3 move through regulatory and commercial stages.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Pfizer, head to the community page for Pfizer to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.